Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 591.21 BATS BZX Real-Time Price As of 2:02pm ET |  +0.26 / +0.04%Today’s Change | 538.01 Today|||52-Week Range 747.42 | -6.38% Year-to-Date |
Latest REGN News | Press Releases
| Regeneron (REGN) Dips More Than Broader Markets: What You Should Know Jun 30 / Zacks.com - Paid Partner Content | Regeneron (REGN) Gains But Lags Market: What You Should Know Jun 24 / Zacks.com - Paid Partner Content |
| Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted Jun 30 / Zacks.com - Paid Partner Content | Regeneron (REGN) Dips More Than Broader Markets: What You Should Know Jun 22 / Zacks.com - Paid Partner Content |
| Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? Jun 29 / Zacks.com - Paid Partner Content | Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last? Jun 20 / Zacks.com - Paid Partner Content |
| Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA Jun 25 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 590.95 |
| Today’s open | 588.86 |
| Day’s range | 586.21 - 595.21 |
| Volume | 9,492 |
| Average volume (3 months) | 689,903 |
| Market cap | $67.3B |
Data as of 2:02pm ET, 07/01/2022
Growth & Valuation
| Earnings growth (last year) | +133.99% |
| Earnings growth (this year) | -41.76% |
| Earnings growth (next 5 years) | +1.50% |
| Revenue growth (last year) | +89.14% |
| P/E ratio | 8.4 |
| Price/Sales | 4.41 |
| Price/Book | 3.55 |
Financials
| Next reporting date | August 4, 2022 |
| EPS forecast (this quarter) | $10.06 |
| Annual revenue (last year) | $16.1B |
| Annual profit (last year) | $8.1B |
| Net profit margin | 50.25% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
